Global Biosimilars Strategic Business Market Report

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Biosimilars Strategic Business Market Report 2016-2022 - Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars

Dublin, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biosimilars - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 71 companies including many key and niche players such as

  • Amgen Inc. (US)
  • Allergan Plc. (Ireland)
  • Biocon Ltd. (India)
  • Biopartners GmbH (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Celltrion Inc. (South Korea)
  • Cipla Ltd. (India)
  • Cipla BioTec Private Ltd. (India)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Eli Lilly and Company (US)
  • EPIRUS Biopharmaceuticals, Inc. (US)
  • Hospira, Inc. (US)
  • Intas Biopharmaceuticals Ltd. (India)
  • Merck KGaA (Germany)
  • Mylan N.V. (US)
  • Pfizer Inc. (US)
  • Samsung Bioepis Co., Ltd. (Korea)
  • Sandoz International GmbH (Germany)
  • STADA Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)

Key Topics Covered: 1. MARKET OVERVIEW Introduction to Biosimilars Biosimilars Set to Revolutionize Healthcare Sector Biosimilars Offer Great Promise despite Challenges Specific Guidelines for Biosimilars in Various Countries with Year of Publication List of Approved Biosimilars & Pending Biosimilar Applications in the EU List of Approved Biosimilars & Pending Biosimilar Applications in the US List of Approved Biosimilars in South Korea Biosimilars Find More Growth in Emerging Markets Comparison of Entry Barriers for Biogenerics in Select Global Markets Market Drivers Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Cost Containment Measures Growing Aging Population Presence of Major Players Growth Restraints Uncertain Regulations High Lead-time High Manufacturing Costs Delivery and Commercialization Automatic Substitution Other Impediments to Market Acceptance Strategies to Aid Survival of Companies 2. RECENT BIOSIMILAR APPROVALS AND PIPELINE ANALYSIS Biosimilar Approvals in 2016, 2015, & 2014 Select Biosimilar Candidates in Late-Stage Pipeline: 2016 Biosimilars in Pipeline for Major Biologic Drugs: 2016 Increasing Collaborations, Licensing Routes and Partnerships Indian & Chinese Companies to Emerge Strong in Western Markets Improved Regulatory Framework European Union Ahead in the Biosimilars Race Biosimilars Regulatory Agencies in Select Regional Markets US Passes Act to Create Biosimilars Pathway, Finally 3. MARKET DYNAMICS & TRENDS Increased Penetration of Biosimilars Implications for Manufacturers Efforts to Push Up Biosimilar Adoption Improvements in Nomenclature and Interchangeability Contract Manufacturing Favored by Emerging & Major Biosimilar Players Companies Eye Human Insulin Biosimilars Monoclonal Antibodies A Key Growth Segment for Biosimilars Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014 Biobetters: Potential Industry Challenge? High Cost of Biologics Favorable for Biosimilars Growing Biosimilars Market A Clear Advantage for Bioseparation Technologies 4. GLOBAL BIOLOGICS MARKET Global Biopharmaceutical Drug Market A Primer US The Largest Biologics Market Worldwide Increasing Share of Biotechnological Drugs to Drive Biosimilars Market Intensifying Consolidation Activity Recent M&A Activity in the Biologics Industry: 2014 & 2015 5. PRODUCT OVERVIEW Introduction Characteristics of Biosimilars Biological Drugs Biological Drugs Manufacturing Process Development Cycle of Biosimilars Industry Participants 6. PRODUCT APPROVALS/INTRODUCTIONS Mylan and Biocon Co-develop trastuzumab Biosimilar EC Approves Remicade Biosimilar Flixabi® Developed by Samsung Bioepis Samsung's BLA for Remicade Biosimilar Accepted by USFDA EMA Approves rituximab Biosimilar Developed by Sandoz EC Approves New Route of Administration for Sandoz's Biosimilar Binocrit USFDA Approves INFLECTRA, Celltrion's Biosimilar to Remicade Japanese Ministry Approves Biocon's Biosimilar Insulin Glargine EMA Accepts Sandoz's MAA for Neulasta Biosimilar FDA Accepts Amgen's BLA for ABP-501 7. RECENT INDUSTRY ACTIVITY Alvotech Acquires Baliopharm GmbH Dr. Reddy's Inks Collaboration Agreement with TR-Pharm Premier and Oncobiologics Collaborate to Enhance Biosimilars Adoption Sandoz Acquires Rights to infliximab Biosimilar from Pfizer Sandoz Enters into Exclusive License Agreement with Kyowa Hakko Kirin Mylan Enters Into Biosimilars Development Partnership with Momenta Pharmaceuticals Merck to Bring Biosimilars to Canada through its Agreement with Samsung EPIRUS Biopharmaceuticals to Expand Biosimilar Pipeline through Acquisition of Bioceros Pfizer Acquires Hospira Astrazeneca Enters into JV with Fujifilm Kyowa Kirin Biologics 8. FOCUS ON SELECT MARKET PLAYERS 9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 71 (including Divisions/Subsidiaries 77)

  • The United States (15)
  • Canada (1)
  • Japan (3)
  • Europe (25)
  • - France (1)
  • - Germany (8)
  • - The United Kingdom (5)
  • - Spain (1)
  • - Rest of Europe (10)
  • Asia-Pacific (Excluding Japan) (30)
  • Latin America (1)
  • Middle-East (2)

For more information about this report visit http://www.researchandmarkets.com/research/v3...iosimilars Related Topics: Biosimilars and Biosuperiors

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Scroll down for more posts ▼

Top 10 Most Recent News Articles

1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 23

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 63

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading